Fulltext

Impact of low-level viraemia on virological failure among Asian children with perinatally acquired HIV on first-line combination antiretroviral treatment: a multicentre, retrospective cohort study

Sudjaritruk T 1 , Teeraananchai S 2 , Kariminia A 3 , Lapphra K 4 , Kumarasamy N 5 , Fong MS 6 Show all authors , Hansudewechakul R 7 , Bunupuradah T 2 , Ly PS 8 , Nallusamy RA 9 , Sohn AH 10 , Sirisanthana V 11 , TREAT Asia Pediatric HIV Observational Database of IeDEA Asia-Pacific

Affiliations 

  • 1 Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
  • 2 The HIV Netherlands Australia Thailand Research Collaboration, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand
  • 3 The Kirby Institute, UNSW Australia, Sydney, Australia
  • 4 Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
  • 5 Chennai Antiviral Research and Treatment Clinical Research Site, VHS-Infectious Diseases Medical Centre, VHS, Chennai, India
  • 6 Hospital Likas, Kota Kinabalu, Malaysia
  • 7 Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand
  • 8 National Centre for HIV/AIDS, Dermatology and STDs, Phnom Penh, Cambodia
  • 9 Penang Hospital, Penang, Malaysia
  • 10 TREAT Asia/amfAR - The Foundation for AIDS Research, Bangkok, Thailand
  • 11 Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand
J Int AIDS Soc, 2020 Jul;23(7):e25550.
PMID: 32628816 DOI: 10.1002/jia2.25550

Abstract

INTRODUCTION: The clinical relevance of low-level viraemia (LLV) and virological outcomes among children living with HIV (CLHIV) remains controversial. This study aimed to determine the impact of LLV on virological failure (VF) among Asian CLHIV on first-line combination antiretroviral therapy (cART).

METHODS: CLHIV aged <18 years, who were on first-line cART for ≥12 months, and had virological suppression (two consecutive plasma viral load [pVL] <50 copies/mL) were included. Those who started treatment with mono/dual antiretroviral therapy, had a history of treatment interruption >14 days, or received treatment and care at sites with a pVL lower limit of detection >50 copies/mL were excluded. LLV was defined as a pVL 50 to 1000 copies/mL, and VF as a single pVL >1000 copies/mL. Baseline was the time of the second pVL 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications